Written question asked by Lord Booth (Conservative) on Tuesday, 2 June 2026, in the House of Lords. It was due for an answer on Tuesday, 16 June 2026. It was answered by Baroness Merron (Labour) on Wednesday, 10 June 2026 on behalf of the Department of Health and Social Care.
Cardiovascular Diseases: Semaglutide
- Question
-
To ask His Majesty's Government, further to the Written Answer by Baroness Merron on 29 April (HL16182), whether they will publish the final NICE guidance for the use of semaglutide.
- Answer
-
The National Institute for Health and Care Excellence published final technology appraisal guidance on the use of semaglutide for reducing the risk of major adverse cardiovascular events in people with cardiovascular disease and overweight or obesity on 7 May 2026.
Secondary information
- Type
- Written question
- Reference
- HL543
- Session
- 2026-27
- Related items
- Subjects
- Cardiovascular diseases Semaglutide
- Link
- View this Written question on www.parliament.uk
Librarians' tools
- Timestamp
- 2026-06-30 12:52:41 +0100
- URI
- http://data.parliament.uk/writtenparliamentaryquestion/lords/2026-27/HL543
- In Indexing
- http://indexing.parliament.uk/Content/Edit/1?uri=http://data.parliament.uk/writtenparliamentaryquestion/lords/2026-27/HL543
- In Solr
- https://search.parliament.uk/claw/solr/?id=http://data.parliament.uk/writtenparliamentaryquestion/lords/2026-27/HL543